{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T11:48:45Z","timestamp":1785930525868,"version":"3.56.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,5]]},"DOI":"10.7759\/cureus.113997","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T11:38:57Z","timestamp":1785929937000},"source":"Crossref","is-referenced-by-count":0,"title":["Dual Autoimmunity: Evans Syndrome and Multiple Sclerosis"],"prefix":"10.7759","author":[{"given":"Alexa","family":"Markl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"Warren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Iskander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camryn","family":"Warren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Faisal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akash","family":"Parashar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-215368","article-title":"The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases","volume":"114","author":"Michel M","year":"2009","unstructured":"Michel M, Chanet V, Dechartres A, et al.. The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases. Blood. 2009, 114:3167-72. 10.1182\/blood-2009-04-215368","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2018.1.382","article-title":"Autoimmune hemolytic anemia","volume":"2018","author":"Hill A","year":"2018","unstructured":"Hill A, Hill QA. Autoimmune hemolytic anemia. Hematology Am Soc Hematol Educ Program. 2018, 2018:382-9. 10.1182\/asheducation-2018.1.382","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s12979-020-00208-7","article-title":"Autoimmune hemolytic anemia: current knowledge and perspectives","volume":"17","author":"Michalak SS","year":"2020","unstructured":"Michalak SS, Olewicz-Gawlik A, Rupa-Matysek J, Wolny-Rokicka E, Nowakowska E, Gil L. Autoimmune hemolytic anemia: current knowledge and perspectives. Immun Ageing. 2020, 17:38. 10.1186\/s12979-020-00208-7","journal-title":"Immun Ageing"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25084296","article-title":"Autoimmune hemolytic anemias: classifications, pathophysiology, diagnoses and management","volume":"25","author":"Loriamini M","year":"2024","unstructured":"Loriamini M, Cserti-Gazdewich C, Branch DR. Autoimmune hemolytic anemias: classifications, pathophysiology, diagnoses and management. Int J Mol Sci. 2024, 25:4296. 10.3390\/ijms25084296","journal-title":"Int J Mol Sci"},{"key":"ref5","article-title":"Laboratory evaluation of immune hemolytic anemias","author":"Tripathi AK","year":"2024","unstructured":"Tripathi AK, Chuda R. Laboratory evaluation of immune hemolytic anemias. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2024."},{"key":"ref6","article-title":"Immune thrombocytopenia","author":"Pietras NM","year":"2024","unstructured":"Pietras NM, Gupta N, Justiz Vaillant AA, Pearson-Shaver AL. Immune thrombocytopenia. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2024."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group","volume":"113","author":"Rodeghiero F","year":"2009","unstructured":"Rodeghiero F, Stasi R, Gernsheimer T, et al.. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009, 113:2386-93. 10.1182\/blood-2008-07-162503","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2147\/OAEM.S331675","article-title":"Assessment and management of immune thrombocytopenia (ITP) in the emergency department: current perspectives","volume":"14","author":"Zitek T","year":"2022","unstructured":"Zitek T, Weber L, Pinzon D, Warren N. Assessment and management of immune thrombocytopenia (ITP) in the emergency department: current perspectives. Open Access Emerg Med. 2022, 14:25-34. 10.2147\/OAEM.S331675","journal-title":"Open Access Emerg Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjhh.2015.03.002","article-title":"Experience with Evans syndrome in an academic referral center","volume":"37","author":"Jaime-P\u00e9rez JC","year":"2015","unstructured":"Jaime-P\u00e9rez JC, Guerra-Leal LN, L\u00f3pez-Razo ON, M\u00e9ndez-Ram\u00edrez N, G\u00f3mez-Almaguer D. Experience with Evans syndrome in an academic referral center. Rev Bras Hematol Hemoter. 2015, 37:230-5. 10.1016\/j.bjhh.2015.03.002","journal-title":"Rev Bras Hematol Hemoter"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2011.07.004","article-title":"Evans syndrome and systemic lupus erythematosus: clinical presentation and outcome","volume":"79","author":"Costallat GL","year":"2012","unstructured":"Costallat GL, Appenzeller S, Costallat LT. Evans syndrome and systemic lupus erythematosus: clinical presentation and outcome. Joint Bone Spine. 2012, 79:362-4. 10.1016\/j.jbspin.2011.07.004","journal-title":"Joint Bone Spine"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-239525","article-title":"Identifying autoimmune lymphoproliferative syndrome in children with Evans syndrome: a multi-institutional study","volume":"115","author":"Seif AE","year":"2010","unstructured":"Seif AE, Manno CS, Sheen C, Grupp SA, Teachey DT. Identifying autoimmune lymphoproliferative syndrome in children with Evans syndrome: a multi-institutional study. Blood. 2010, 115:2142-5. 10.1182\/blood-2009-08-239525","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.radcr.2024.09.053","article-title":"Evans syndrome in conjunction with rheumatoid arthritis and SLE: a unique case of autoimmune intersection","volume":"19","author":"Hashim HT","year":"2024","unstructured":"Hashim HT, Al-Obaidi AD, Al-Fatlawi N, et al.. Evans syndrome in conjunction with rheumatoid arthritis and SLE: a unique case of autoimmune intersection. Radiol Case Rep. 2024, 19:6323-7. 10.1016\/j.radcr.2024.09.053","journal-title":"Radiol Case Rep"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-017-2268-3","article-title":"Steroid-resistant autoimmune myelofibrosis in a patient with autoimmune hepatitis and Evans syndrome complicated with increased expression of TGF-\u03b2 in the bone marrow: a case report","volume":"106","author":"Ohkawara H","year":"2017","unstructured":"Ohkawara H, Furukawa M, Ikeda K, et al.. Steroid-resistant autoimmune myelofibrosis in a patient with autoimmune hepatitis and Evans syndrome complicated with increased expression of TGF-\u03b2 in the bone marrow: a case report. Int J Hematol. 2017, 106:718-24. 10.1007\/s12185-017-2268-3","journal-title":"Int J Hematol"},{"key":"ref14","article-title":"The co-occurrence of multiple sclerosis and Evans syndrome: a case report","volume":"11","author":"Salehizadeh S","year":"2020","unstructured":"Salehizadeh S, Naser Moghadasi A, Sahrain MA. The co-occurrence of multiple sclerosis and Evans syndrome: a case report. Caspian J Intern Med. 2020, 11:343-5.","journal-title":"Caspian J Intern Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1172\/JCI58649","article-title":"Multiple sclerosis","volume":"122","author":"Nylander A","year":"2012","unstructured":"Nylander A, Hafler DA. Multiple sclerosis. J Clin Invest. 2012, 122:1180-8. 10.1172\/JCI58649","journal-title":"J Clin Invest"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1126\/science.aav7188","article-title":"Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility","volume":"365","year":"2019","unstructured":"Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science. 2019, 365.10.1126\/science.aav7188","journal-title":"Science"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2020-322941","article-title":"Complete Epstein-Barr virus seropositivity in a large cohort of patients with early multiple sclerosis","volume":"91","author":"Abrahamyan S","year":"2020","unstructured":"Abrahamyan S, Ebersp\u00e4cher B, Hoshi MM, et al.. Complete Epstein-Barr virus seropositivity in a large cohort of patients with early multiple sclerosis. J Neurol Neurosurg Psychiatry. 2020, 91:681-6. 10.1136\/jnnp-2020-322941","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2018-320189","article-title":"Latitude continues to be significantly associated with the prevalence of multiple sclerosis: an updated meta-analysis","volume":"90","author":"Simpson S Jr","year":"2019","unstructured":"Simpson S Jr, Wang W, Otahal P, Blizzard L, van der Mei IA, Taylor BV. Latitude continues to be significantly associated with the prevalence of multiple sclerosis: an updated meta-analysis. J Neurol Neurosurg Psychiatry. 2019, 90:1193-200. 10.1136\/jnnp-2018-320189","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.61.8.1032","article-title":"Environmental risk factors in multiple sclerosis: causes, triggers, and patient autonomy","volume":"61","author":"Franklin GM","year":"2003","unstructured":"Franklin GM, Nelson L. Environmental risk factors in multiple sclerosis: causes, triggers, and patient autonomy. Neurology. 2003, 61:1032-4. 10.1212\/wnl.61.8.1032","journal-title":"Neurology"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13198","article-title":"The role of B cells in the immunopathogenesis of multiple sclerosis","volume":"160","author":"Gharibi T","year":"2020","unstructured":"Gharibi T, Babaloo Z, Hosseini A, Marofi F, Ebrahimi-Kalan A, Jahandideh S, Baradaran B. The role of B cells in the immunopathogenesis of multiple sclerosis. Immunology. 2020, 160:325-35. 10.1111\/imm.13198","journal-title":"Immunology"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2008.070690","article-title":"Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis","volume":"172","author":"Tzartos JS","year":"2008","unstructured":"Tzartos JS, Friese MA, Craner MJ, Palace J, Newcombe J, Esiri MM, Fugger L. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol. 2008, 172:146-55. 10.2353\/ajpath.2008.070690","journal-title":"Am J Pathol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/nm1651","article-title":"Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation","volume":"13","author":"Kebir H","year":"2007","unstructured":"Kebir H, Kreymborg K, Ifergan I, et al.. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med. 2007, 13:1173-5. 10.1038\/nm1651","journal-title":"Nat Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1038\/nm1714","article-title":"Matching of oligoclonal immunoglobulin transcriptomes and proteomes of cerebrospinal fluid in multiple sclerosis","volume":"14","author":"Obermeier B","year":"2008","unstructured":"Obermeier B, Mentele R, Malotka J, et al.. Matching of oligoclonal immunoglobulin transcriptomes and proteomes of cerebrospinal fluid in multiple sclerosis. Nat Med. 2008, 14:688-93. 10.1038\/nm1714","journal-title":"Nat Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(24)00144-3","article-title":"Diagnosis and management of Evans syndrome in adults: first consensus recommendations","volume":"11","author":"Fattizzo B","year":"2024","unstructured":"Fattizzo B, Marchetti M, Michel M, et al.. Diagnosis and management of Evans syndrome in adults: first consensus recommendations. Lancet Haematol. 2024, 11:e617-28. 10.1016\/s2352-3026(24)00144-3","journal-title":"Lancet Haematol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9123851","article-title":"Evans' syndrome: from diagnosis to treatment","volume":"9","author":"Audia S","year":"2020","unstructured":"Audia S, Grienay N, Mounier M, Michel M, Bonnotte B. Evans' syndrome: from diagnosis to treatment. J Clin Med. 2020, 9:3851. 10.3390\/jcm9123851","journal-title":"J Clin Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1215216","article-title":"Rituximab resistance in ITP and beyond","volume":"14","author":"Xiao Z","year":"2023","unstructured":"Xiao Z, Murakhovskaya I. Rituximab resistance in ITP and beyond. Front Immunol. 2023, 14:1215216. 10.3389\/fimmu.2023.1215216","journal-title":"Front Immunol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-491415","article-title":"Preferential splenic CD8+ T-cell activation in rituximab-nonresponder patients with immune thrombocytopenia","volume":"122","author":"Audia S","year":"2013","unstructured":"Audia S, Samson M, Mah\u00e9vas M, et al.. Preferential splenic CD8+ T-cell activation in rituximab-nonresponder patients with immune thrombocytopenia. Blood. 2013, 122:2477-86. 10.1182\/blood-2013-03-491415","journal-title":"Blood"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/254319","article-title":"Introducing polyautoimmunity: secondary autoimmune diseases no longer exist","volume":"2012","author":"Rojas-Villarraga A","year":"2012","unstructured":"Rojas-Villarraga A, Amaya-Amaya J, Rodriguez-Rodriguez A, Mantilla RD, Anaya JM. Introducing polyautoimmunity: secondary autoimmune diseases no longer exist. Autoimmune Dis. 2012, 2012:254319. 10.1155\/2012\/254319","journal-title":"Autoimmune Dis"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12308","article-title":"Polyautoimmunity in a Greek cohort of multiple sclerosis","volume":"131","author":"Deretzi G","year":"2015","unstructured":"Deretzi G, Kountouras J, Polyzos SA, et al.. Polyautoimmunity in a Greek cohort of multiple sclerosis. Acta Neurol Scand. 2015, 131:225-30. 10.1111\/ane.12308","journal-title":"Acta Neurol Scand"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-05824-7","article-title":"Efficacy and safety of fostamatinib in refractory immune thrombocytopenia: a meta-analysis from randomized controlled trials","volume":"103","author":"Tungjitviboonkun S","year":"2024","unstructured":"Tungjitviboonkun S, Bumrungratanayos N, Jitwimungsanon J, Kheamakulvanich T, Siramongkholkarn S. Efficacy and safety of fostamatinib in refractory immune thrombocytopenia: a meta-analysis from randomized controlled trials. Ann Hematol. 2024, 103:3357-68. 10.1007\/s00277-024-05824-7","journal-title":"Ann Hematol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25125","article-title":"Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials","volume":"93","author":"Bussel J","year":"2018","unstructured":"Bussel J, Arnold DM, Grossbard E, et al.. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials. Am J Hematol. 2018, 93:921-30. 10.1002\/ajh.25125","journal-title":"Am J Hematol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13336","article-title":"Long-term remission rates after splenectomy in adults with Evans syndrome compared to immune thrombocytopenia: a single-center retrospective study","volume":"104","author":"Sulpizio ED","year":"2020","unstructured":"Sulpizio ED, Raghunathan V, Shatzel JJ, Zilberman-Rudenko J, Worrest T, Sheppard BC, DeLoughery TG. Long-term remission rates after splenectomy in adults with Evans syndrome compared to immune thrombocytopenia: a single-center retrospective study. Eur J Haematol. 2020, 104:55-8. 10.1111\/ejh.13336","journal-title":"Eur J Haematol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12636","article-title":"Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factors","volume":"12","author":"Ruggeri M","year":"2014","unstructured":"Ruggeri M, Tosetto A, Palandri F, et al.. Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factors. J Thromb Haemost. 2014, 12:1266-73. 10.1111\/jth.12636","journal-title":"J Thromb Haemost"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.261099","article-title":"Splenectomy for immune thrombocytopenia: the evolution and preservation of treatment","volume":"105","author":"Remiker A","year":"2020","unstructured":"Remiker A, Neunert C. Splenectomy for immune thrombocytopenia: the evolution and preservation of treatment. Haematologica. 2020, 105:2507-9. 10.3324\/haematol.2020.261099","journal-title":"Haematologica"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2025.101322","article-title":"Evans syndrome revisited","volume":"74","author":"Jiang D","year":"2025","unstructured":"Jiang D, Kuter DJ. Evans syndrome revisited. Blood Rev. 2025, 74:101322. 10.1016\/j.blre.2025.101322","journal-title":"Blood Rev"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/512544-dual-autoimmunity-evans-syndrome-and-multiple-sclerosis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T11:38:58Z","timestamp":1785929938000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/512544-dual-autoimmunity-evans-syndrome-and-multiple-sclerosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":35,"URL":"https:\/\/doi.org\/10.7759\/cureus.113997","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,5]]}}}